Literature DB >> 25862488

Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.

Lauren A Gillory1, Jerry E Stewart1, Michael L Megison1, Alicia M Waters1, Elizabeth A Beierle2.   

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood and is responsible for over 15% of pediatric cancer deaths. Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that is important in many facets of neuroblastoma tumor development and progression. The p53 oncogene, although wild type in most neuroblastomas, lacks significant function as a tumor suppressor in these tumors. Recent reports have found that FAK and p53 interact in some tumor types. We have hypothesized FAK and p53 coordinately control each other's expression and also interact in neuroblastoma. In the present study, we showed that not only do FAK and p53 interact but each one controls the expression of the other. In addition, we also examined the effects of FAK inhibition combined with p53 activation in neuroblastoma and showed that these two, in combination, had a synergistic effect on neuroblastoma cell survival. The findings from this present study help to further our understanding of the regulation of neuroblastoma tumorigenesis and may provide novel therapeutic strategies and targets for neuroblastoma and other pediatric solid tumors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FAK; Neuroblastoma; SH-EP; WAC(2); p53

Mesh:

Substances:

Year:  2015        PMID: 25862488      PMCID: PMC4442704          DOI: 10.1016/j.jss.2015.03.021

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  48 in total

1.  Focal adhesion kinase inhibitors are potent anti-angiogenic agents.

Authors:  Miguel A Cabrita; Laura M Jones; Jennifer L Quizi; Luc A Sabourin; Bruce C McKay; Christina L Addison
Journal:  Mol Oncol       Date:  2011-10-20       Impact factor: 6.603

2.  The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells.

Authors:  L H Xu; X Yang; R J Craven; W G Cance
Journal:  Cell Growth Differ       Date:  1998-12

3.  Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry.

Authors:  S J Cotterill; L Parker; L More; A W Craft
Journal:  Med Pediatr Oncol       Date:  2001-01

4.  Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.

Authors:  Charles S Smith; Vita M Golubovskaya; Erin Peck; Li-Hui Xu; Brett P Monia; Xihui Yang; William G Cance
Journal:  Melanoma Res       Date:  2005-10       Impact factor: 3.599

5.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

Authors:  D A Tweddle; A J Malcolm; M Cole; A D Pearson; J Lunec
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

6.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

Authors:  P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov
Journal:  Science       Date:  1999-09-10       Impact factor: 47.728

7.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Andrew Slack; Zaowen Chen; Roberto Tonelli; Martin Pule; Lisa Hunt; Andrea Pession; Jason M Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein.

Authors:  Elena Kurenova; Li-Hui Xu; Xihui Yang; Albert S Baldwin; Rolf J Craven; Steven K Hanks; Zheng-Gang Liu; William G Cance
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

10.  Induction of cytoplasmic accumulation of p53: a mechanism for low levels of arsenic exposure to predispose cells for malignant transformation.

Authors:  Yelin Huang; Jianglin Zhang; Kevin T McHenry; Mihee M Kim; Weiqi Zeng; Vanessa Lopez-Pajares; Christian C Dibble; Joseph P Mizgerd; Zhi-Min Yuan
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more
  13 in total

1.  Hypoxia inducible factor 1α promotes survival of mesenchymal stem cells under hypoxia.

Authors:  Bingke Lv; Feng Li; Jie Fang; Limin Xu; Chengmei Sun; Jianbang Han; Tian Hua; Zhongfei Zhang; Zhiming Feng; Xiaodan Jiang
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

2.  A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.

Authors:  Adele P Williams; Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2018-03-26       Impact factor: 2.192

3.  Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.

Authors:  Jiaxiong Lu; Shan Guan; Yanling Zhao; Yang Yu; Yongfeng Wang; Yonghua Shi; Xinfang Mao; Kristine L Yang; Wenjing Sun; Xin Xu; Joanna S Yi; Tianshu Yang; Jianhua Yang; Jed G Nuchtern
Journal:  Oncotarget       Date:  2016-12-13

4.  Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.

Authors:  Laura L Stafman; Smitha Mruthyunjayappa; Alicia M Waters; Evan F Garner; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal:  Oncotarget       Date:  2018-04-27

5.  Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.

Authors:  Laura L Stafman; Adele P Williams; Evan F Garner; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  Transl Oncol       Date:  2018-11-06       Impact factor: 4.243

Review 6.  The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.

Authors:  Jin Zhou; Qian Yi; Liling Tang
Journal:  J Exp Clin Cancer Res       Date:  2019-06-11

7.  Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.

Authors:  Laura L Stafman; Adele P Williams; Raoud Marayati; Jamie M Aye; Hooper R Markert; Evan F Garner; Colin H Quinn; Shoeb B Lallani; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  Sci Rep       Date:  2019-09-13       Impact factor: 4.379

Review 8.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

Review 9.  β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.

Authors:  Anne-Florence Blandin; Guillaume Renner; Maxime Lehmann; Isabelle Lelong-Rebel; Sophie Martin; Monique Dontenwill
Journal:  Front Pharmacol       Date:  2015-11-24       Impact factor: 5.810

10.  FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.

Authors:  Evan F Garner; Adele P Williams; Laura L Stafman; Jamie M Aye; Elizabeth Mroczek-Musulman; Blake P Moore; Jerry E Stewart; Gregory K Friedman; Elizabeth A Beierle
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.